TREATMENT OF POOR PROGNOSIS BURKITTS-LYMPHOMA IN ADULTS WITH THE SOCIETE-FRANCAISE-DONCOLOGIE-PEDIATRIQUE LMB PROTOCOL - A STUDY OF THE FEDERATION-NATIONALE-DES-CENTERS-DE-LUTTE-CONTRE-LE-CANCER (FNLCC)

被引:20
作者
PHILIP, T
MECKENSTOCK, R
DECONNICK, E
CARRIE, C
BAILLY, C
COLOMBAT, P
DAURIAC, C
DEMAILLE, MC
SALLES, B
CAHN, JY
TURPIN, F
BIRON, P
机构
[1] HOP BRETONNEAU, DEPT HEMATOL, F-37044 TOURS, FRANCE
[2] HOP PONTCHAILLOU, DEPT HEMATOL, F-35003 RENNES, FRANCE
[3] CTR OSCAR LAMBRET, DEPT ONCOL, F-59020 LILLE, FRANCE
[4] CTR HOSP CHALON SUR SAONE, DEPT ONCOL, F-71321 CHALON SUR SAONE, FRANCE
[5] CHU BESANCON, HOP MINJOZ, F-25030 BESANCON, FRANCE
[6] CTR RENE HUGUENIN, F-92211 ST CLOUD, FRANCE
关键词
D O I
10.1016/0959-8049(92)90235-T
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
14 adult patients between 16 and 50 years old with small non-cleaved cell lymphoma (Burkitt's lymphoma) were prospectively treated from 1982 to 1990 with the LMB protocols of the Societe Francaise d'Oncologie Pediatrique (SFOP). No HIV-positive patients were included. All patients had extensive disease with bad prognosis factors, i.e. 10 patients had Murphy stage III and 4 had stage IV with bone marrow involvement. The LMB protocols were characterised by high-dose fractionated cyclophosphamide, high-dose methotrexate (HD-MTX), and cytosine arabinoside. No local or central nervous system irradiation was used. Treatment duration ranged from 5 (LMB 84) to 12 (LMB 81) months. There were no therapy-related deaths. All patients achieved complete remission (CR). 6 patients relapsed between 2 and 30 months following CR. 8 of the 14 patients (57%) are still alive and disease-free after treatment by LMB protocol alone. 2 patients were salvaged with bone marrow transplantation after relapse and a total of 10 out of 14 patients (71%) are disease-free at the time of this report. Our results showed the high curability of advanced Burkitt's lymphoma using a paediatric protocol, even in adult patients. The LMB protocol may be applied to adult patients but requires intensive care during the induction period.
引用
收藏
页码:1954 / 1959
页数:6
相关论文
共 45 条
[1]   CHILDHOOD NON-HODGKINS LYMPHOMA - THE RESULTS OF A RANDOMIZED THERAPEUTIC TRIAL COMPARING A 4-DRUG REGIMEN (COMP) WITH A 10-DRUG REGIMEN (LSA2-L2) [J].
ANDERSON, JR ;
WILSON, JF ;
JENKIN, RDT ;
MEADOWS, AT ;
KERSEY, J ;
CHILCOTE, RR ;
COCCIA, P ;
EXELBY, P ;
KUSHNER, J ;
SIEGEL, S ;
HAMMOND, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (10) :559-565
[2]   COMBINED MODALITY THERAPY FOR ADULTS WITH SMALL NONCLEAVED CELL LYMPHOMA (BURKITTS AND NON-BURKITTS TYPES) [J].
BERNSTEIN, JI ;
COLEMAN, CN ;
STRICKLER, JG ;
DORFMAN, RF ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :847-858
[3]  
BURKITT DP, 1967, CANCER, V64, P756
[4]  
CANELLOS GP, 1981, CANCER TREAT REP, V65, P125
[5]   LNH-84 REGIMEN - A MULTICENTER STUDY OF INTENSIVE CHEMOTHERAPY IN 737 PATIENTS WITH AGGRESSIVE MALIGNANT-LYMPHOMA [J].
COIFFIER, B ;
GISSELBRECHT, C ;
HERBRECHT, R ;
TILLY, H ;
BOSLY, A ;
BROUSSE, N .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1018-1026
[6]  
DEVITA VT, 1975, LANCET, V1, P248
[7]  
DEVITA VT, 1988, SEMIN HEMATOL, V25, P2
[8]  
DUQUEHAMMERSHAIMB L, 1983, CANCER, V52, P39, DOI 10.1002/1097-0142(19830701)52:1<39::AID-CNCR2820520109>3.0.CO
[9]  
2-S
[10]  
ERSBOLL J, 1985, CANCER, V55, P2442, DOI 10.1002/1097-0142(19850515)55:10<2442::AID-CNCR2820551024>3.0.CO